ClinicalTrials.gg
Not yet recruitingNCT07944625Updated Nov 18, 2026

Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease

A Phase 3 interventional study of Larazotide Acetate and Placebo in Celiac Disease and Celiac Disease in Adolescents, sponsored by Interlude Biopharma Co.. Not yet recruiting. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Interlude Biopharma Co. · Phase 3, Interventional, and Prevention

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
414
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if larazotide acetate, which will be tested at two doses and compared to placebo, can help prevent signs and symptoms of celiac disease in patients with well-controlled celiac disease who are following a gluten-free diet. Both adults and children (ages 12 years and up) will be allowed to enroll in this study.

Read the detailed description

Larazotide acetate is being studied as a preventative therapy in individuals with well-controlled celiac disease. The primary objective of the study is to evaluate the protective effects of larazotide acetate compared to placebo on histologic changes and patient-reported outcomes following simulated inadvertent gluten exposure.

A total of 414 patients will be randomized 1:1:1 to receive either 0.25 mg larazotide acetate, 0.5 mg larazotide acetate, or placebo. All three study arms will take the assigned treatment as an oral capsule three times daily (TID). The treatment period will be 14 weeks, with an up to 8-week screening period and a 4-week follow-up period. During parts of the study, participants will also eat daily food bars that may contain a small amount of gluten, to simulate inadvertent gluten exposure in the real world. The doses of larazotide acetate being evaluated in this study were selected as the most promising doses to maximize efficacy based on previous clinical data.

Efficacy will be assessed via patient-reported outcomes, including but not limited to a daily and two weekly patient questionnaires, and histological changes, as evaluated via endoscopies with duodenal biopsy at screening/baseline and at the end of the treatment period. Safety will be assessed via adverse event reporting, laboratory evaluations, vital sign evaluations, and physical examinations at regular intervals.

02

Conditions studied

  • Celiac Disease
  • Celiac Disease in Adolescents

Browse trials for

Keywords

  • Celiac Disease
  • Gluten-Sensitive Enteropathy
  • Controlled Gluten Exposure
  • Histopathology
  • Symptom Prevention
  • Gastrointestinal Symptoms
  • Villous Atrophy
03

In context

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

This study's planned enrollment of 414 is above the median of 50 across 215 interventional studies indexed under Celiac Disease.

Browse Celiac Disease studies →

Lead sponsor

This is the only study on the registry with Interlude Biopharma Co. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is male or female ≥ 12 and ≤ 80 years of age.
  2. Participant has a (BMI) between 16 and 45 kg/m2, inclusive.
  3. Participant has -proven CeD confirmed by medical records.
  4. Participant has IgA anti-tissue transglutaminase (tTG) antibodies ≤1.5 times the during screening.
  5. Participant is willing to undergo all assessments in the protocol, including two esophagogastroduodenoscopies with duodenal biopsies (i.e., baseline and Week 14).
  6. Participant has followed a gluten-free diet (GFD) for at least 12 consecutive months immediately prior to screening and is willing to maintain this diet for the duration of the study.
  7. Participant is willing and able to refrain from taking prohibited medications during the study.
  8. If taking medications for chronic use, the subject has been on a stable dose for ≥ 4 weeks prior to screening and has no plans to change during the study.
  9. Participant is capable of understanding the requirements of the study, is willing to comply with all study procedures, understands the language of the /assent form, and is capable and willing to sign the informed consent/assent form.
  10. Participant has a Weekly CDSD GI symptom severity score ≤ 0.400 AND participant has no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days), AND no individual GI symptom scores of severe or greater severity (a score of ≥3) for core GI symptoms of CeD (i.e., abdominal pain, bloating, diarrhea, and nausea), as measured by the CDSD v2.1 symptom severity score during the symptom eligibility screening period (Visit 2). Note: Participants must meet symptom criteria to undergo baseline EGD.
  11. Participant has a Vh:Cd ratio ≥2.5 at the time of baseline endoscopy (i.e., within 14 days prior to randomization).

Exclusion criteria

Exclusion Criteria:

  1. Participant is diagnosed with inflammatory or other GI disease or systemic disease other than CeD that either has the potential to cause persistent GI symptoms similar to CeD or is not well controlled without the use of excluded medication, including but not limited to: Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), eosinophilic esophagitis, gastroparesis, colitis, Type 1 diabetes, autoimmune hepatitis, primary biliary cirrhosis, and systemic lupus erythematosus.
  2. Participant has a history of dermatitis herpetiformis.
  3. Participant has known or suspected type 2 CeD or ulcerative jejunitis.
  4. Participant has selective IgA deficiency.
  5. Participant has a diagnosis of small intestinal bacterial overgrowth within 3 months prior to screening.
  6. Participant has ongoing pancreatic insufficiency.
  7. Participant has a known reaction and/or allergy, including anaphylaxis, to the study drug or any of its components, wheat and/or gluten, or any other ingredients in SIGE bar.
  8. Participant had major GI surgery within the last six months prior to screening.
  9. Ongoing systemic treatment, systemic treatment, or treatment with immunosuppressant or corticosteroids in the 12 weeks before screening.
  10. Participant has received oral, intramuscular (IM), or intravenous (IV) antibiotics within four weeks prior to screening.
  11. Participant has ongoing chronic use (defined as >7 days continuous use) of a nonsteroidal anti-inflammatory drug (aside from ≤100 mg aspirin, daily, for prophylactic use).
  12. Participant has ongoing use, or use in the 3 months before screening, of medications known to cause villous abnormalities (such as, but not limited to: mycophenolate mofetil, angiotensin receptor blockers, colchicine).
  13. Participant has used treatments for GI signs and/or symptoms, including antiemetics, antidiarrheals, antispasmodics, and medical marijuana (use of medical marijuana indicated for non-GI conditions is not exclusionary) within 2 weeks prior to and during the Screening period. Participants on a stable dose (i.e., more than 4 weeks) of an osmotic, bulking-forming, or emollient (surface active agent) laxative are eligible, provided symptoms are considered not related to CeD in the investigator's opinion.
  14. Participant initiated treatment with a GLP-1 receptor agonist or GLP-1-containing combination therapy or experienced a dose change in their GLP-1 receptor agonist or GLP-1-containing combination therapy regimen within 12 weeks prior to Screening. Participants receiving a stable dose for at least 12 weeks prior to Screening are eligible.
  15. Participant has received an product within 30 days prior to screening, or the subject intends to participate in another clinical study while participating in this study.
  16. Participant has received treatment for alcohol or drug abuse in the past year.
  17. Participant has a known history of (HIV), or C infection.
  18. Participant has a diagnosis of cancer occurring within five years prior to study entry. NOTE: Participant diagnosed with non-melanoma skin cancer, cervical carcinoma-in-situ, or early-stage prostate cancer that has been treated successfully with curative therapy at least one year prior to study entry, as demonstrated by medical records, is exempt from this exclusion criteria.
  19. Participant has any co-morbid disease or clinically significant abnormal laboratory test results that would make the subject unsuitable for enrollment, as determined by the Principal Investigator or qualified designee and confirmed by the study Medical Monitor.
  20. Participant is pregnant or lactating.
  21. Participant has and is unwilling to use an acceptable method of for the duration of the study. Acceptable methods of birth control include:

    1. Use of double barrier methods (e.g., diaphragm, cervical cap, or condom [male or female] and spermicidal gel, foam, sponges, or film)
    2. Use of an intrauterine device (IUD)
    3. Hormonal contraception (e.g., oral, patch, vaginal ring, implanted or injectable hormonal contraceptive)
    4. Surgical sterilization (vasectomy for men or bilateral oophorectomy, hysterectomy, or tubal ligation for women)
    5. (12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy)
    6. To be a monogamous partner of a sterile male is an acceptable method of birth control. Abstinence is acceptable as long as female participants agree to use contraception if and when they are sexually active.
  22. Noncompliance with baseline diary entries (>3 missing diary entries from Symptom Eligibility Period).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
414 participants (estimated)

Study arms

  • Experimental
    Larazotide Acetate 0.25 mg

    Oral administration of 0.25 mg larazotide acetate capsules, TID, for 14 weeks.

    Drug: Larazotide Acetate

  • Experimental
    Larazotide Acetate 0.5 mg

    Oral administration of 0.5 mg larazotide acetate capsules, TID, for 14 weeks.

    Drug: Larazotide Acetate

  • Placebo comparator
    Placebo

    Oral administration of placebo capsules, TID, for 14 weeks.

    Drug: Placebo

Interventions

  • Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks.

  • DrugPlacebo

    Placebo capsules will be taken orally TID for 14 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of responders treatment with larazotide acetate (0.25 mg or 0.5 mg) compared to placebo during the last two weeks of the 14-week treatment period

    Responders are defined as participants who continue to meet the baseline criteria for well-controlled CeD, based on both symptom and histologic parameters, as outlined below: * Participant has a Weekly Celiac Disease Symptom Diary (CDSD) GI symptom severity score ≤ 0.400, with no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days), and no individual GI symptom scores of severe or greater severity (a score of ≥3), for core GI symptoms of CeD (i.e., abdominal pain, bloating, diarrhea, and nausea), as measured by the CDSD v2.1 symptom severity score during the last two weeks of the 14-week treatment period (Weeks 13 to 14) * Participant has a Villous Height to Crypt Depth (Vh:Cd) ratio ≥2.5 at the end of the 14-week treatment period

    Time frame: Last two weeks of the treatment period (Weeks 13-14)

Secondary outcomes

  1. Proportion of participants with a Vh:Cd ratio ≥2.5 at the end of the 14-week treatment period.

    Vh:Cd ratio will be determined based on the Week 14 endoscopy with duodenal biopsy. Higher Vh:Cd ratios indicate a lesser extent of damage.

    Time frame: End of treatment (Week 14)

  2. Proportion of participants with a Weekly CDSD GI symptom severity score ≤ 0.400, with no persistent moderate score and no severe score, for core GI symptoms, during the last two weeks of the 14-week treatment period

    The Weekly CDSD GI symptom severity score is an average of the daily GI symptom severity scores during the past 7 days. Higher scores indicate worse symptom severity. No persistent moderate score = no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days) No severe score = no individual GI symptom scores of severe or greater severity (a score of ≥3) Core GI symptoms of CeD = abdominal pain, bloating, diarrhea, and nausea, as measured by the CDSD v2.1 symptom severity score during the last two weeks of the 14-week treatment period.

    Time frame: Last two weeks of the treatment period (Weeks 13-14)

  3. Mean change from baseline in Vh:Cd ratio at the end of the 14-week treatment period

    Vh:Cd ratios will be determined based on the endoscopy with duodenal biopsy from screening/baseline and Week 14. A higher Vh:Cd ratio indicates a lesser extent of damage.

    Time frame: Baseline and End of treatment (Week 14)

  4. Change from baseline in intraepithelial lymphocyte (IEL) density at the end of the 14-week treatment period

    IEL density will be determined based on the endoscopy with duodenal biopsy from screening/baseline and Week 14. A higher IEL density indicates increased disease activity.

    Time frame: Baseline and End of treatment (Week 14)

  5. Proportion of weeks maintaining well-controlled disease-related symptoms during the 14-week treatment period

    Well-controlled disease-related symptoms is defined as a Weekly CDSD GI symptom severity score ≤ 0.400, with no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days), and no individual GI symptom scores of severe or greater severity (a score of ≥3), for core GI symptoms of CeD (i.e., abdominal pain, bloating, diarrhea, and nausea), as measured by the CDSD v2.1 symptom severity score.

    Time frame: Entire treatment period (14 weeks)

  6. Proportion of symptom-free days, defined as no core GI symptoms of CeD for a 24-hour period

    A symptom-free day is when all four core GI symptom scores (abdominal pain, bloating, diarrhea, nausea) are 0 during a 24-hour period, as measured by the CDSD v2.1 symptom severity score.

    Time frame: Entire treatment period (14 weeks)

Other outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Time frame: First treatment through end of follow-up (~Week 18)

  2. Incidence of treatment-related adverse events

    Time frame: First treatment through end of follow-up (~Week 18)

  3. Incidence of serious adverse events

    Time frame: First treatment through end of follow-up (~Week 18)

  4. Incidence of treatment-emergent adverse events and serious adverse events leading to discontinuation of study medication

    Time frame: First treatment through end of treatment (Week 14)

  5. Change from baseline in systolic blood pressure

    Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)

  6. Change from baseline in diastolic blood pressure

    Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)

  7. Change from baseline in heart rate

    Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)

  8. Change from baseline in respiratory rate

    Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)

  9. Change from baseline in oral temperature

    Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)

  10. Change from baseline in weight

    Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)

  11. Change from baseline in Body Mass Index

    Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2027; primary completion for Aug 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 18, 2026
StartEst.
Feb 2027
Primary completionEst.
Aug 2028
CompletionEst.
Sep 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944625
Lead sponsor
Interlude Biopharma Co.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Feb 2027 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jay Madan
Contact
info@interludebio.com
919-995-4130

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larazotide acetate

Start the discussion